J. Penfield

发表

What nephrologists need to know about gadolinium

R. Reilly, Robert F Reilly, J. Penfield, 2007, Nature Clinical Practice Nephrology.

Intensity of renal support in critically ill patients with acute kidney injury (New England Journal of Medicine (2008) 359, (7-20))

B. Efron, G. Koch, M. Rocco, 2009 .

HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Multiple Myeloma in End‐Stage Renal Disease

J. Penfield, Jeffrey G. Penfield, 2006, Seminars in dialysis.

The associations between orthostatic blood pressure changes and extracellular volume in hemodialysis patients

H. Jeon‐Slaughter, J. Penfield, Peter N Van Buren, 2021, Hemodialysis international. International Symposium on Home Hemodialysis.

Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents

J. Penfield, 2008, Pediatric Nephrology.

NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium‐Based Contrast Agents?

R. Reilly, J. Penfield, 2008 .

Docosahexaenoic acid, a constituent of fetal and neonatal serum, inhibits nitric oxide production by murine macrophages stimulated by IFNγ plus LPS, or by IFNγ plus Listeria monocytogenes

Christopher Y. Lu, M. Kielar, J. Penfield, 1998 .

Syngeneic renal transplantation increases the number of renal dendritic cells in the rat.

D. Jeyarajah, A. Ar’rajab, Christopher Y. Lu, 1999, Transplant immunology.

Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney.

Y. Wang, S. Li, D. Jeyarajah, 1999, Kidney international.

Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?

R. Reilly, J. Penfield, Jeffrey G. Penfield, 2011, Seminars in dialysis.

What nephrologists need to know about gadolinium

R. Reilly, J. Penfield, 2007, Nature Clinical Practice Nephrology.